TPWA
NKTR icon

Twin Peaks Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$384 Buy
+5
New +$285 ﹤0.01% 2073

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Twin Peaks Wealth Advisors's NKTR Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 5 shares worth $384. The stake represents ﹤0.01% of the portfolio and ranks #2073 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Twin Peaks Wealth Advisors held 5 shares of Nektar Therapeutics worth $384 as of Q1 2026.
  • Nektar Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2073 holding.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.